| Disposition of 5-methyltetrahydrohomofolate in mice, dogs, and monkeys. | |
| | |
MedLine Citation:
|
PMID: 109197 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The pharmacologic disposition of [methyl-14C]5-methyltetrahydrohomofolate (MTHHF) has been studied in mice, dogs, and monkeys after parenteral administration of doses of 150 and 1500 mg/m2. Thin-layer chromatography and high-pressure liquid chromatography were used to separate the parent compound from its products. Following ip injection of MTHHF into mice, serum levels rose to a maximum within 1 hour and decreased with a half-life of about 50 minutes. The liver, kidneys, and small intestine of mice contained concentrations of MTHHF greater than that of serum. For dogs and monkeys given an iv injection of MTHHF, serum levels declined in three phases. The third phase was probably associated primarily with loss of the drug from the liver and intestine, where relatively large amounts were retained. Within 24 hours after administration of MTHHF, the percent recovery in the urine was 69% for mice, 78% for dogs, and 50%--60% for monkeys. For mice and dogs an additional 2%--17% was recovered in the feces within 24 hours. Over a period of 3 days after injection with the high dose in a monkey, 24% of the dose was present in the feces. For all three species, 90%--99% of the radioactivity in the serum, urine, and feces was unchanged MTHHF, indicating that very little metabolism or decomposition had occurred. Less than 0.3% of the dose was recovered from monkeys as radioactive CO2. |
| | |
Authors:
|
S M El Dareer; K F Tillery; D L Hill |
Related Documents
:
|
16914457 - Gamma-ray spectroscopic analysis of selected samples from nile river sediments in upper... 8827677 - Two new oral chemical biomarkers for coyotes. 3760747 - [3h]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. 10680977 - Uptake by hepatocytes and biliary excretion of intravenously administered polystyrene m... 2035747 - Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity... 1983347 - The effects of 15 days of dosing with placebo, sufotidine 600 mg nocte or sufotidine 60... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Cancer treatment reports Volume: 63 ISSN: 0361-5960 ISO Abbreviation: Cancer Treat Rep Publication Date: 1979 Feb |
Date Detail:
|
Created Date: 1979-09-01 Completed Date: 1979-09-01 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7607107 Medline TA: Cancer Treat Rep Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 201-7 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blood Proteins / metabolism Dogs Female Folic Acid / administration & dosage, analogs & derivatives*, metabolism Haplorhini Male Metabolic Clearance Rate Mice Species Specificity Tissue Distribution |
| Chemical | |
Reg. No./Substance:
|
0/Blood Proteins; 59-30-3/Folic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Variable oral absorption of hexamethylmelamine in man.
Next Document: The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentat...